Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.
作者信息
Nannini Esteban C, Pai Suresh R, Singh Kavindra V, Murray Barbara E
机构信息
Center for the Study of Emerging and Re-Emerging Pathogens, Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical School, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2003 Feb;47(2):529-32. doi: 10.1128/AAC.47.2.529-532.2003.
Abstract
A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peritonitis against three Enterococcus faecalis and four Enterococcus faecium isolates with different susceptibilities to vancomycin and tetracyclines, all of which were inhibited by </=0.125 micro g of tigecycline/ml. Using a single subcutaneous dose, tigecycline displayed a protective effect (50% protective dose, </=5.7 mg/kg of body weight) against all strains tested, including two with Tn925 (from the Tn916 family), which contains the Tet(M) tetracycline resistance determinant, as well as VanA and VanB strains. As expected, tetracycline and minocycline were ineffective against the isolates carrying Tn925.
摘要
相似文献
1
Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.
Antimicrob Agents Chemother. 2003 Feb;47(2):529-32. doi: 10.1128/AAC.47.2.529-532.2003.
2
In vitro activity of eravacycline and mechanisms of resistance in enterococci.
Int J Antimicrob Agents. 2020 Dec;56(6):106215. doi: 10.1016/j.ijantimicag.2020.106215. Epub 2020 Oct 27.
3
Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis.
Antimicrob Agents Chemother. 2003 Jan;47(1):216-22. doi: 10.1128/AAC.47.1.216-222.2003.
4
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Antimicrob Agents Chemother. 1999 Apr;43(4):738-44. doi: 10.1128/AAC.43.4.738.
5
Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
APMIS. 2010 Jan;118(1):66-73. doi: 10.1111/j.1600-0463.2009.02559.x.
6
Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.
Antimicrob Agents Chemother. 2000 Nov;44(11):3022-7. doi: 10.1128/AAC.44.11.3022-3027.2000.
7
Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
J Biochem Mol Biol. 2007 Nov 30;40(6):881-7. doi: 10.5483/bmbrep.2007.40.6.881.
8
Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination.
Pharmacotherapy. 2002 Dec;22(12):1517-23. doi: 10.1592/phco.22.17.1517.34117.
9
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36. doi: 10.1016/s0732-8893(99)00092-9.
10
Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet(L) and tet(M).
J Antimicrob Chemother. 2016 Apr;71(4):871-81. doi: 10.1093/jac/dkv420. Epub 2015 Dec 18.
引用本文的文献
1
Efficacy of Omadacycline against Multidrug-Resistant Enterococcus faecium Strains in a Mouse Peritonitis Model.
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0070921. doi: 10.1128/AAC.00709-21.
2
Efficacy of Tedizolid against Enterococci and Staphylococci, Including Strains, in a Mouse Peritonitis Model.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02627-18. Print 2019 Apr.
3
Synthesis and evaluation of 1,2,4-triazolo[1,5-a]pyrimidines as antibacterial agents against Enterococcus faecium.
J Med Chem. 2015 May 28;58(10):4194-203. doi: 10.1021/jm501831g. Epub 2015 May 12.
4
Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.
Antimicrob Agents Chemother. 2015 Jul;59(7):4301-4. doi: 10.1128/AAC.00323-15. Epub 2015 Apr 20.
5
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections.
Core Evid. 2006;1(3):181-94. Epub 2006 Mar 31.
6
Dogs leaving the ICU carry a very large multi-drug resistant enterococcal population with capacity for biofilm formation and horizontal gene transfer.
PLoS One. 2011;6(7):e22451. doi: 10.1371/journal.pone.0022451. Epub 2011 Jul 19.
7
Clinical pharmacokinetics and pharmacodynamics of tigecycline.
Clin Pharmacokinet. 2009;48(9):575-84. doi: 10.2165/11317100-000000000-00000.
8
Tigecycline: a novel glycylcycline.
Drugs. 2005;65(10):1317-36. doi: 10.2165/00003495-200565100-00002.
9
Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.
Antimicrob Agents Chemother. 2005 Apr;49(4):1656-9. doi: 10.1128/AAC.49.4.1656-1659.2005.
本文引用的文献
1
National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001.
Am J Infect Control. 2001 Dec;29(6):404-21. doi: 10.1067/mic.2001.119952.
2
Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model.
Antimicrob Agents Chemother. 2000 Dec;44(12):3434-7. doi: 10.1128/AAC.44.12.3434-3437.2000.
3
Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.
Antimicrob Agents Chemother. 2000 Nov;44(11):3022-7. doi: 10.1128/AAC.44.11.3022-3027.2000.
4
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9. doi: 10.1128/AAC.44.8.2225-2229.2000.
5
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36. doi: 10.1016/s0732-8893(99)00092-9.
6
Nosocomial bloodstream infections in United States hospitals: a three-year analysis.
Clin Infect Dis. 1999 Aug;29(2):239-44. doi: 10.1086/520192.
7
Enterococcal bacteremia in children: a review of seventy-five episodes in a pediatric hospital.
Pediatr Infect Dis J. 1998 Dec;17(12):1154-8. doi: 10.1097/00006454-199812000-00011.
8
Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model.
J Infect Dis. 1998 Nov;178(5):1416-20. doi: 10.1086/314453.
9
Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants.
Antimicrob Agents Chemother. 1998 Aug;42(8):1871-7. doi: 10.1128/AAC.42.8.1871.
10
Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution.
FEMS Microbiol Rev. 1996 Oct;19(1):1-24. doi: 10.1111/j.1574-6976.1996.tb00251.x.
Zotero 插件